Femasys Inc. (FEMY) Stock Score, Valuation & Financial Research
Femasys Inc. is in the Healthcare sector and Medical - Instruments & Supplies industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 16/100.
Quick answer for FEMY
Femasys Inc. currently has a Wall Street Score of 16/100. The stored market price is $2.77. Its financial score is 14/100. Its valuation score is 0/100. The latest WSS change is +0.1 points. These figures are a research snapshot, not a buy or sell recommendation.
What Femasys Inc. does
Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as FemBloc and FemChec, alongside FemaSeed, which is an artificial insemination offering. For diagnostic purposes, Femasys provides FemCerv, a biopsy device utilized for endocervical curettage, and FemEMB, a product candidate intended for endometrial sampling to assist in the detection of uterine cancer. Additionally, the company markets its FemVue saline-air device across various international regions, including the U.S., Europe, Canada, and Japan. Its infertility-related products are supplied to obstetrician-gynecologists, other allied healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. The compa
FEMY financial snapshot
- Wall Street Score:
- 16/100
- Current price:
- $2.77
- Market capitalization:
- $8.3M
- Revenue:
- $2.3M
- Net income:
- $-12.3M
- Free cash flow:
- $-19.2M
- Cash:
- $1.4M
- Total debt:
- $4.8M
- EPS:
- -4.56
- Financial score:
- 14/100
- Valuation score:
- 0/100
- Revenue score:
- 23/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $-19.2M, showing cash burn in the current stored period.
- The balance sheet shows $1.4M of cash versus $4.8M of total debt, so leverage deserves attention.
- The latest Wall Street Score change is +0.1 points: FEMY increased 0.1 points because overall fundamentals improved.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 14/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-08.
How to research FEMY
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.